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Research articleThe dynamics of nasopharyngeal streptococcus 
pneumoniae carriage among rural Gambian 
mother-infant pairs
Momodou K Darboe*1, Anthony JC Fulford1, Ousman Secka2 and Andrew M Prentice1
Abstract
Background: Streptococcus pneumoniae is an important cause of community acquired pneumonia, sepsis, meningitis 
and otitis media globally and has been incriminated as a major cause of serious childhood bacterial infections in The 
Gambia. Better understanding of the dynamics of transmission and carriage will inform control strategies.
Methods: This study was conducted among 196 mother-infant pairs recruited at birth from six villages in the West 
Kiang region of The Gambia. Nasopharyngeal swabs were collected from mother-infant pairs at birth (within 12 hours 
of delivery), 2, 5 and 12 months. Standard techniques of culture were used to identify carriage and serotype S. 
pneumoniae.
Results: Of 46 serotypes identified, the 6 most common, 6A, 6B, 14, 15, 19F and 23F, accounted for 67.3% of the isolates 
from infants. Carriage of any serotype among infants rose from 1.5% at birth to plateau at approximately 80% by 2 m 
(prevalence at 2 m = 77%; 5 m = 86%; 12 m = 78%). Likewise, maternal carriage almost doubled in the first 2 months 
post-partum and remained elevated for the next 10 m (prevalence at birth = 13%; 2 m = 24%; 5 m = 22%; 12 m = 21%). 
Carriage was significantly seasonal in both infants and mothers with a peak in December and lowest transmission in 
August. The total number of different serotypes we isolated from each infant varied and less than would be expected 
had the serotypes assorted independently. In contrast, this variability was much as expected among mothers. The half-
life of a serotype colony was estimated to be 1.90 m (CI95%: 1.66-2.21) in infants and 0.75 m (CI95%: 0.55-1.19) in mothers. 
While the odds for a serotype to be isolated from an infant increased by 9-fold if it had also been isolated from the 
mother, the population attributable fraction (PAF) of pneumococcal carriage in infants due to maternal carriage was 
only 9.5%. Some marked differences in dynamics were observed between vaccine and non-vaccine serotypes.
Conclusions: Colonisation of the nasopharynx in Gambian infants by S. pneumoniae is rapid and highly dynamic. 
Immunity or inter-serotype competition may play a role in the dynamics. Reducing mother-infant transmission would 
have a minimal effect on infant carriage.
Background
Streptococcus pneumoniae is a leading cause of invasive
bacterial meningitis, acute respiratory infections and
pneumonia among infants and children less than two
years in developing countries [1]. Approximately 2.6 mil-
lion preschool children die from pneumonia annually in
developing countries, and almost half of these deaths are
attributable to S. pneumoniae either exclusively or in con-
junction with viral infections and/or malnutrition [2-5].
Nasopharyngeal carriage of S. pneumoniae is a risk fac-
tor for the development of respiratory diseases and pneu-
monia [6-8]. Although the relationship between carriage
and disease is not well understood, evidence suggests that
local or systemic invasive infection is caused by serotypes
that bind to the epithelial surface of the respiratory tract
[9-11]. Nasopharyngeal carriage is also the source of
pneumococcal spread to other individuals mainly in inti-
mate and overcrowded conditions. For example day-care
centers are notorious for S. pneumoniae carriage and
transmission among both day-care attendees and their
siblings [12,13]. Over 80% of apparently healthy Gambian
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infants are nasopharyngeal pneumococcal carriers
[14,15]. Carriage is also relatively high (50%) among
Gambian adults [15].
S. pneumoniae is the most common cause of invasive
bacterial disease (IBD) among Gambian children [16-18],
with the highest rates occurring in infancy. Early diagno-
sis and treatment with antibiotics has been a successful
strategy of managing cases but the emergence of drug
resistant serotypes is making this strategy increasingly
less effective and costly [19,20]. The search for a vaccine
that would induce strong immunity against S. pneumo-
niae infection is therefore essential.
A randomised controlled trial of a 9-valent pneumo-
coccal conjugate vaccine (PCV-9) among Gambian chil-
dren was 77% efficacious against invasive pneumococcal
disease caused by vaccine serotypes, 50% against disease
caused by all serotypes, and 15% and 16% against all-
cause admissions and mortality respectively [21]. Intro-
duction of the same vaccine among day-care attendees in
Israel reduced carriage of the vaccine serotypes, which
are most associated with antibiotic resistance among
recipients [22]. It is therefore very likely that introducing
a higher valent PCV would be more effective in control-
ling both nasopharyngeal carriage and IPD. However, it is
important to understand the distribution and dynamics
of the carriage of the serotypes including those covered
and those not covered by such a vaccine.
The collection of nasopharyngeal swabs from 196
mother/infant pairs during a high-dose vitamin A study
conducted in six rural Gambian villages [14] offered an
opportunity for us to study the longitudinal distribution
and dynamics of pneumococcal carriage. We employed
novel statistical techniques to describe the transmission
and dynamics of carriage.
Methods
The study described here formed part of a randomised
placebo-controlled early-high-dose vitamin A supple-
mentation trial, which was set up to test whether the new
International Vitamin A consultative Group's recom-
mended early high-dose regime of vitamin A supplemen-
tation would increase maternal and infant plasma vitamin
A, reduce infant Helicobacter pylori infections and
nasopharyngeal pneumococcal carriage and improve
infant gut epithelial integrity. The study was conducted in
six villages in the West Kiang region of The Gambia.
Detailed description of the study area and population,
including the methods of subject randomisation, recruit-
ment and follow-up were given elsewhere [14]; only the
methods used in the pneumococcal carriage component
will be briefly discussed here. A total of 196 mother-
infant pairs from the six villages were included in this
study. Subjects were recruited from birth after comple-
tion of the appropriate consent procedures. The study
protocol was explained to the subjects and their consent
sought and confirmed by a formal signature/thumb print
of the consent form. Subjects were followed for 12
months.
Sample collection
Trained field assistants collected nasopharyngeal swabs
from mother-infant pairs at birth (within 12 hrs of deliv-
ery), 2, 5 and 12 months using a sterile paediatric calcium
alginate swab with flexible aluminium shaft (Fisher
brand, Fisher Scientific UK Ltd, Loughborough, Leices-
tershire). All samples were collected in the clinic during
the "study days" except those at birth which were col-
lected in the subject's home or where she delivered. The
swabs were immediately inoculated into 1 ml vials of
skim milk tryptone-glucose-glycerin transport medium
and brought to the laboratory in cold boxes within two
hours of collection. The vials were then vortexed for 15
sec and then stored at -70°C until transported to the labo-
ratory at MRC Fajara for further processing.
Laboratory analysis
Standard techniques for culturing, isolation and serotyp-
ing were used to identify pneumococcal serotypes [23].
The frozen specimens were left to fully thaw at room
temperature and then mixed thoroughly before being
streaked onto selective agar plates of 5 mg/L gentamicin-
trypticase soy agar with 5% sheep blood. The plates were
then incubated overnight at 37°C in 5% CO2. Phenotypic
characteristic of morphological analysis and α-haemoly-
sis were used for presumptive identification of pneumo-
cocci colonies. Three to four colonies with typical
pneumococci morphology were selected and pneumo-
cocci confirmed by Optochin susceptibility and bile solu-
bility test. The Optochin test involved sub-culturing of
the colonies by streaking out each of the selected colonies
on one half of two of the selective agar plates and placing
an optochin disc in the centre of the streaks. The plates
were then incubated overnight as before. A positive cul-
ture of S. pneumoniae with optochin disc had an inhibi-
tion zone of at least 14 mm around the disc and a negative
culture had no inhibition zone. A single positive colony
was then selected from each of the streaks and serotyped
by Quellung reaction. Serotypes were categorised under
vaccine and non-vaccine types based on the 13 valent
vaccine which consists of serotypes 1, 3, 4, 5, 6A, 6B, 7F,
9V, 14, 18C, 19A, 19F and 23F for data analysis.
Ethical approval
The study was approved by the MRC Scientific Coordi-
nating Committee, the joint MRC and Gambia Govern-
ment Ethics Committee and the Ethics Committee of the
London School of Hygiene and Tropical Medicine, UK.
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Statistical Methods
Tabulation, Pearson χ2 tests and logit- and log-linked
binomial regression were performed with Stata version 9
(StatCorp LP, TX, USA).
Serotype data from the four time points were consid-
ered in separate and pooled logistic regression analyses,
and also combined as a binary "ever detected" variable, in
which individuals scored one if the serotype was detect at
one or more time point, zero if not. Whenever the pres-
ence or absence of serotype was the dependent variable
(i.e. analyses of age, sex and seasonality and the estima-
tion of OR in the calculation of PAF, but not the regres-
sion used to estimate half-life - see below) the data were
analysed with logistic regression. In all these logistic
regression models, serotype differences were fitted using
the single term logit(serotype prevalence). This was used
because more conventional models fitting serotype as a
fixed categorical factor or a random effect were unstable,
sometimes failing to converge (probably because the
approximations made by these models break down when
the prevalence of many serotypes is very low).
In all regression analyses (now including both the logis-
tic and log-linked binomial regression) in which time
points were pooled we applied robust (Huber-White)
standard errors to account for between-individual varia-
tion. This was preferred to the less stable multi-level
models with individual modelled as a random effect.
Seasonality was fitted using a truncated Fourier series
[24]. Briefly, in this case, the first two pairs of Fourier
terms (sinθ, cosθ and sin2θ, cos2θ, where θ is the angle in
radians representing the point in the annual cycle at
which the observation was made) were entered as inde-
pendent variables in logistic regression models.
We estimated the contribution of mother-to-child
transmission to infant carriage by considering the
increased risk of an infant carrying a particular serotype
if the mother carries the same serotype. This requires a
slight modification of the standard population attribut-
able fraction (PAF) calculation in order to accommodate
stratification by serotype. We first calculate the PAF for
each serotype using the standard formula:
Where:
Pe = proportion of children exposed, i.e. serotype preva-
lence among mothers,
AF = attributable fraction = (RR-1)/RR,
RR = risk ratio (risk if exposed/risk if not exposed) = Ie /
Iu
Iu = serotype prevalence among unexposed infants,
Ie = serotype prevalence among exposed infants,.
Pe is readily calculated for each serotype but RR, and
hence AF, estimates for serotypes with low prevalence are
very inaccurate and unreliable. Instead we obtain a com-
mon estimate of OR for all serotypes from logistic regres-
sion and used the relationship AF = (1-Iu).(OR-1)/OR to
calculate the serotype-specific AF. A score reflecting the
overall fraction of infant pneumococcal carriage attribut-
able to maternal carriage was then obtained by taking a
weighted average of the serotype-specific PAFs with
weights equal to the serotype prevalence among infants.
The 95% confidence interval we give for the overall PAF
was based on the precision of the OR estimate. (Note, this
does not take into account imprecision in the estimation
of the serotype prevalences; the confidence interval gives
the precision of our estimate of the PAF for a population
with serotype prevalence structure exactly as we estimate.
This should provide a reasonably representative figure.
Making allowance for imprecision in the prevalence esti-
mation would be relevant only for the particular situation
in Kiang West at the time of the study).
A permutation test was devised to compare the distri-
bution of the observed number of serotypes per individ-
ual with that predicted assuming that the serotypes were
distributed independently. To do this we first simulated
the carriage of each serotype for each of 100,000 individ-
uals such that the probability that a particular individual
"carried" a particular serotype was equal to its observed
prevalence at the time point of interest (or, in the case of
the "ever-carried" variable, the proportion of individuals
in which it was observed). Thus the assignment of a sero-
type to an individual was made independently of which
other serotypes the individual carried and of the carriage
of other individuals. Next, counting how many serotypes
each "carried", we calculated the expected proportions of
individuals carrying 0, 1, 2, etc serotypes and multiplying
these by 196 we obtained the corresponding expected fre-
quency in our sample. Then we used Pearson's χ2-test to
compare this simulated distribution with the observed
frequencies. We also calculated the ratio of the observed
to expected variance and estimated its 95% confidence
interval by assuming that the sum of squares divided by
the expected variance should approximately follow a χ2-
distribution under the null hypothesis. (We note that the
bootstrap yielded an almost identical confidence inter-
val.) This analysis was carried out on an MS-Excel work-
sheet.
In order to calculate the half-life of pneumococcal colo-
nies in infants and their mothers we first defined a vari-
able indicating, for each serotype, individual and time
point (other than birth), whether the serotype had been
lost since the previous time point. If the serotype had not
been isolated at the previous time point the variable was
coded unknown. This variable was regressed on the
length of the interval (in months) between the current
PAF P AF 1 1 P AFe e= − −( )⎡⎣ ⎤⎦. / .
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and previous time points using log-linked binomial
regression with no constant and the rate of colony loss
estimated from the regression coefficient, β: colony half-
life = log(0.5)/β.
Difference in dynamics between serotypes is of consid-
erable interest. However, individual serotype prevalences
are mostly very low, so fixed or random effects models
were deemed impractical. Instead we concentrated on the
broad differences between vaccine and non-vaccine sero-
types.
Results
Serotype distribution
A total of 1568 nasopharyngeal swabs were taken from all
196 mothers and their infants at each of four time points.
These yielded 741 isolates and a total of 46 identified
serotypes. Table 1 shows the distribution of serotype
prevalence. Ninety eight percent of children carried
pneumococci at some point during the study and all 13-
valent pneumococcal conjugate vaccine serotypes (Table
1) were isolated from both infants and mothers.
Infant's age and sex
The percentage of infants carrying at least one serotype
increased rapidly from 1.5% at birth to 77% at 2 months of
age, remaining fairly constant thereafter. Maternal car-
riage doubled over the same interval and remained ele-
vated thereafter (Table 1). There is some evidence that
this pattern differed between serotypes: logistic regres-
sion demonstrated a significant interaction between time
point (i.e. infant's age) and whether the serotype was a
vaccine or non-vaccine serotype (X2 = 14.3 on 3 df; p =
0.0025): while vaccine serotypes continued to increase in
prevalence with infant age, the non-vaccine serotypes
reached a peak and by one year had fallen well below their
levels at five months (Fig 1). A similar pattern was seen
among mothers, although the prevalences were lower, the
power weak and the interaction not significant.
The inclusion of a term for infant's sex did not signifi-
cantly improve these models and was excluded from sub-
sequent analysis.
Seasonality
The pattern of carriage for both infants and mothers was
significantly seasonal: in a logistic regression model con-
trolling for serotype prevalence and time point (infant's
age) the first two pairs of Fourier terms were found to be
(jointly) significant (children: X2 = 25.4 on 4 df, p <
0.0001; mothers: X2 = 16.9 on 4 df, p = 0.002). While the
pattern appears to be more exaggerated for mothers (Fig
2) fitting separate patterns for mothers and children was
not significantly better than a common pattern (X2 = 7.54
on 4 df, p = 0.11). Similarly, there was no evidence to sug-
gest that the vaccine and non-vaccine serotypes exhibit
different seasonality among children (X2 = 8.00 on 4 df, p
= 0.092).
Distribution of the number of serotypes per individual
The distribution of the number of serotypes ever carried
by infants (i.e. at any of the four time points) differed sig-
nificantly from what would be expected if the serotypes
were assorted independently (X2 = 40.1 on 7 df; p = 1×10-
6. Fig 3(a)). This was due to considerable under-disper-
sion: the variance was 45% of that expected (CI95%: 39% -
58%).
Curiously, there was no evidence that the distribution
of the number of serotypes carried by mothers was
under-dispersed (Fig 3(b)): the variance among mothers
was 105% of that expected and the 95% confidence inter-
val, 87% - 130%.
Rates of loss of serotypes
The estimated half-life of pneumococcal colonies in
infants, 1.90 m (CI95%: 1.66 - 2.21), was significantly lon-
ger than that in mothers, 0.75 m (CI95%: 0.55 - 1.19). Fur-
thermore, vaccine serotypes were, on average, retained
considerably longer than non-vaccine serotypes in both
infants: 2.24 m (CI95%: 1.89 - 2.75) vs 1.51 m (CI95%: 1.25 -
1.91), p = 0.008. A similar pattern is seen for mothers:
1.03 m (CI95%: 0.64 - 2.62) vs 0.58 m (CI95%: 0.43 - 0.91)
although this difference was not significant. Including
either a constant or quadratic term in these models pro-
vided no improvement in fit so we have no evidence to
contradict the assumed exponential decay model or to
suggest that loss was age-dependent (age and interval
length are strongly confounded in this study design).
Relationship between mother's and infant's carriage
It can be seen from Fig 4 that there is a close relationship
between the prevalence of a serotype in infants and its
prevalence in mothers, two exceptions being serotypes
23b and 34 (for the latter it is highly unlikely to be due to
chance) both of which are less prevalent in infants than
expected. Logistic regression shows that the probability
that an infant ever carried a particular serotype is much
increased if their mother ever carried it: OR = 9.1 (CI95%:
6.4 to 13.6). While this value is comparatively high, the
prevalence of most serotypes is low and maternal carriage
accounts for a small percentage of infant carriage: PAF =
9.5% (CI95%: 7.4 to 11.6%) in the "ever carried" analysis.
There was no evidence that this relationship varied
with age (X2 = 3.37 on 2 df; ns). The PAFs estimated sepa-
rately at 2 m was slightly higher than later time points but
the tight and overlapping 95% confidence intervals rule
out anything but a modest age dependence (at 2 m PAF =
10.5%, CI95%: 7.1 to 13.5%; at 5 m PAF = 7.3%, CI95%: 4.5 to
10.1; at 12 m PAF = 7.2%, CI95%: 4.6 to 9.7%).
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Table 1: Distribution of prevalence of vaccine and non-vaccine serotypes listed in order of prevalence among infants
Infants Mothers
non-vaccine
serotypes:
Infant's age (months)
0 2 5 12 ever* 0 2 5 12 ever*
18B 0.0% 0.5% 0.5%
39 0.0% 0.5% 0.5%
48 0.0% 0.5% 0.5%
18A 0.0% 0.5% 0.5% 1.0%
35F 0.0% 0.5% 0.5% 1.0%
35C 0.5% 0.5% 0.0%
47 0.5% 0.5% 0.0%
24 0.5% 0.5% 0.5% 0.5%
9N 0.5% 0.5% 0.5% 0.5%
19C 0.5% 0.5% 0.5% 0.5% 1.0%
20 1.0% 0.5% 1.0% 0.5% 0.5%
2 0.5% 0.5% 1.0% 0.5% 0.5% 0.5% 1.5%
23A 1.0% 0.5% 1.5% 0.5% 0.5%
31 1.0% 0.5% 1.5% 0.5% 0.5%
16 1.0% 1.0% 0.5% 2.0% 0.5% 0.5%
38 0.5% 1.5% 2.0% 0.5% 0.5% 1.0%
17 0.5% 1.5% 2.0% 1.0% 0.5% 1.0% 2.0%
28 1.5% 1.0% 2.0% 1.0% 1.0% 2.0%
22 2.0% 0.5% 2.6% 0.5% 0.5% 1.0%
9L 0.5% 1.5% 1.0% 2.6% 0.5% 0.5% 1.0%
23B 1.5% 1.5% 0.5% 3.1% 1.0% 1.0% 1.0% 1.0% 3.6%
33 2.0% 2.0% 3.6% 1.0% 1.0%
10 3.1% 1.5% 3.6% 1.0% 1.0% 0.5% 2.0%
12 2.6% 2.0% 4.1% 0.0%
7C 3.1% 3.1% 4.1% 1.0% 0.5% 1.5%
19B 1.5% 2.6% 1.5% 4.6% 0.5% 1.0% 0.5% 0.5% 2.6%
9A 4.6% 1.0% 5.6% 1.0% 1.0%
13 2.0% 1.0% 2.6% 5.6% 1.0% 0.5% 1.5%
21 2.6% 2.6% 1.0% 5.6% 1.5% 0.5% 2.0%
11 2.6% 2.0% 2.0% 6.1% 1.5% 1.0% 0.5% 3.1%
35B 2.6% 2.6% 2.0% 6.1% 1.0% 0.5% 2.0% 3.1%
34 0.5% 4.6% 0.5% 1.0% 6.1% 2.6% 1.5% 1.5% 5.1%
15 7.1% 6.1% 6.1% 15.3% 2.0% 0.5% 1.0% 3.6%
any non-vacc 0.5% 43.4% 41.3% 23.0% 73.0% 10.2% 16.8% 13.3% 9.7% 38.8%
13-PCV serotypes:
7F 0.5% 0.5% 0.5% 0.5%
1 0.5% 0.5% 1.0% 0.0%
5 1.0% 1.0% 0.0%
18C † 1.0% 0.5% 1.5% 1.0% 1.0% 2.0%
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The OR is significantly smaller for vaccine serotypes
than others (OR for vaccine serotypes = 5.4, CI95%: 3.1 to
9.6; OR for non-vaccine serotypes = 14.1, CI95%: 8.4 to
23.5; p = 0.018). These translate into a PAF due to mater-
nal carriage of 7.0% (CI95%: 4.4 to 9.6%) for vaccine sero-
types and 13.3 (CI95%: 9.5 to 17.3%) for non-vaccine
serotypes.
These associations include a possible contribution due
to infants infecting their mothers. To eliminate this it is
tempting to consider the association between infant car-
riage at a particular time point with maternal carriage at
the previous time point. However, these correlations were
found to be very weak, probably due to the very short
half-life of colonies in infants and, especially their moth-
ers.
Discussion
While there has been a previous longitudinal study of
nasopharyngeal carriage of S. pneumoniae among Gam-
bian infants [25] ours is the first to study S. pneumoniae
carriage simultaneously among mother-infant pairs in the
Gambia. Our results are consistent with the findings of a
similar study conducted among mother infant pairs in
Papua new Guinea [26]. Our findings provide baseline
information on the dynamics of carriage that we hope
will prove useful in the preparation for the introduction
and evaluation of the 13-valent conjugate pneumococcal
carriage in The Gambia and, more generally, in under-
standing the transmission of the infection in infancy.
The data we report here was obtained from a vitamin A
intervention trial, the results of which were published
earlier [14]. The intervention had no detectable effect on
pneumococcal carriage and its inclusion in the analyses
of transmission had a negligible effect. We have therefore
ignored it in the results we present here.
We have isolated 46 serotypes (serotypes), identified
the most common serotypes of both vaccine and non-
vaccine serotypes and demonstrated that some Gambian
infants already carry nasopharyngeal pneumococci
within 12 hours of delivery and have reached a steady
level of approximately 80% by 2 months of age. This is
consistent with the findings of similar studies carried out
elsewhere [27,28] and in The Gambia by Hill and col-
leagues [15]. Hill et al have demonstrated nasopharyngeal
pneumococcal colonization in Gambian infants as early
as at 7 days postpartum and showed that the mean and
median ages of first acquisition of carriage were 33 and 24
days respectively [25].
In several nasopharyngeal carriage studies, only few
serotypes form the most common serotypes [27,29]. In
our study, 67% of the serotypes ever carried by the infants
are the 6 most common serotypes identified among
infants. Four of these are vaccine serotypes included in
the 7-valent conjugate vaccine (serotypes 4, 6B, 9V, 14,
18C 19F and 23F) forming 92.3% of the vaccine serotypes
ever carried by the infants. In most countries where
immunization with the 7-valent vaccine has been suc-
cessful, over 60% of serotypes have been covered by the
vaccine [30-34]. Only 43% of serotypes carried by infants
in our study are covered by the 7-valent conjugate vac-
cine, a similar figure to that reported for infants by Hill et
al [25]. This is of relevance for the introduction and eval-
uation of the 13-valent conjugate vaccine, although the
picture is confused by results from an earlier study
reporting a coverage of 63% of isolates among Gambian
under-5 year olds [15].
3 1.0% 1.0% 0.5% 2.6% 0.5% 0.5% 0.5% 1.5%
9V † 0.5% 3.1% 3.6% 0.5% 1.0% 1.5%
4 † 2.6% 1.0% 1.0% 4.6% 0.5% 0.5% 0.5% 1.5%
19A 1.5% 5.6% 5.6% 11.2% 0.5% 0.5% 2.6% 0.5% 3.6%
23F † 8.2% 7.1% 6.6% 17.3% 0.5% 0.5% 1.0% 2.6% 4.6%
14 † 4.1% 7.7% 11.2% 20.9% 0.5% 2.0% 1.0% 1.5% 4.1%
6B † 8.7% 15.3% 12.2% 26.5% 1.0% 0.5% 2.0% 1.0% 4.6%
6A 6.6% 12.8% 12.8% 27.0% 0.5% 2.0% 2.6% 5.1%
19F † 1.0% 7.1% 8.2% 15.8% 27.6% 0.5% 0.5% 2.0% 1.0% 4.1%
any vacc 1.0% 39.3% 58.2% 63.3% 89.3% 3.1% 7.7% 11.2% 12.2% 28.6%
any serotype 1.5% 78.1% 87.8% 78.6% 98.0% 13.3% 24.5% 23.5% 21.4% 55.1%
* "ever" here refers to the detection of the serotype at any one of the four time points
† component of 7-valent vaccine
(N = 196 throughout).
Table 1: Distribution of prevalence of vaccine and non-vaccine serotypes listed in order of prevalence among infants 
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Counting the number of serotypes each infant was
observed to have carried at one or more time points gives
a distribution that is considerably, and highly signifi-
cantly, under-dispersed relative to simulations under the
assumption of independent assortment of serotypes
would lead us to expect. There is a strong tendency for
count distributions in nature to be over-dispersed due to
clustering [35]. Under-dispersion is a less commonly
encountered phenomenon and implies that there is some
sort of ordering in the system strong enough to cancel out
the expected clustering. Possible reasons for such order-
ing in this system include cross-immunity between sero-
types, active competition between serotypes or technical
issues associated with the laboratory processing of the
samples. The last of these is of particular concern for the
Optochin method employed here. Before concluding that
the observed under-dispersion reflected a biological phe-
nomenon it would be important to repeat this analysis on
serotype data derived from a PCR-based method. Among
our mothers there was little evidence that serotypes were
not independently assorted and clearly the confidence
interval for the ratio of the observed to the expected vari-
Figure 1 (a) & (b) - Graph of the odds of carriage between vaccine and non-vaccine serotypes among infants and mothers. Pink line = vaccine 
serotypes; Blue line = non-vaccine serotypes. The odds on the y-axis have been scaled (by dividing by the value at 5 m) in order to facilitate visual 
comparison of the patterns.
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ance indicates that levels of under-dispersion similar to
that seen among infants would be highly implausible.
One explanation might be that whatever causes the
under-dispersion among infants is a non-linear process,
disproportionately weaker when the average number of
serotypes carried is lower. Another explanation might be
that mothers' immune systems are already fully primed
with respect to these bacteria; unlike their immunologi-
cally inexperienced infants, seeing more serotypes do not
further change their immunological status. Some support
for this idea is lent by the considerably shorter lifespan of
colonies in mothers than infants. Mothers in our study
carried fewer serotypes on average than children. This is
consistent with a study carried out among mother-infant
pairs from birth in Papua New Guinea, to determine the
age of acquisition and duration of carriage of the first
strains of Haemophilus influenzae and Streptococcus
pneumoniae in the upper respiratory tract [26]. The study
found that mothers, generally either did not carry H.
influenzae or S. pneumoniae, or harboured types differ-
ent to those first acquired by their infants. However, one-
third of mothers subsequently became colonized with H.
influenzae and S. pneumoniae types similar to those car-
ried by their babies.
Previous pneumococcal carriage has been found to be
associated with serotype-independent protection from
subsequent acquisition, whereas recent serotype-specific
exposure within the family has been found to be associ-
ated with an 8-fold increase in the rate of acquisition of
that serotype [36]. This is found to be consistent with the
hypothesis that serotype-independent protective immu-
nity is activated in children by previous carriage and
reduces the rate of new colonisation. Cross immunity in
the system is also consistent with the principle of herd
immunity [37]. Dagan and colleagues have demonstrated
in toddlers an inverse relationship between pneumococ-
cal-conjugate vaccine (PCV) post-vaccination high serum
concentration of serotype-specific pneumococcal anti-
capsular IgG and reduced probability of new acquisition
of carriage [7], suggesting that the magnitude of herd pro-
tection against S. pneumoniae provided by PCV may
depend on the magnitude of IgG concentration. However,
a review by Lipsitch et al suggests that anticapsular anti-
body is not primarily responsible for the age-specific
decline in invasive pneumococcal disease, that other fac-
tors such as age-related anatomical changes and innate or
acquired cellular immune response cannot be ruled out
and that more than one factor may be involved [38].
Not only is colonisation of infants by pneumococcus
rapid, it appears to be a highly dynamic process. The half-
life of a serotype in infants is only 1.9 months and 0.75
months in mothers. (Even these estimates may be inflated
by the loss and subsequent recolonisation of serotypes
during the long interval between swabs. On the other
hand under-estimation of the half-life would result from
less than perfect sensitivity of the detection method.)
After 2 months of age the proportion of children carrying
at least one serotype has reached 77% and remains at
approximately 80% until 12 months of age, although the
serotypes carried at 2 months are rapidly replaced by oth-
ers. This is consistent with the literature[39,40] and, given
the epidemiology of pneumococcal nasopharyngeal car-
riage in this age group [15,16,25], not surprising. A study
in the Gambia found a 79% prevalence of carriage of non-
vaccine serotypes among children vaccinated with 3
doses of pneumococcal conjugate vaccine, compared to a
42.5% prevalence among control children [41]. Active
competition between serotypes has been observed in
populations after the introduction of the 7-valent conju-
gate vaccine [39,40,42] when non-vaccine serotypes
replace vaccine serotypes in a process known as serotype
replacement. Carriage of non-vaccine serotypes
increased among children receiving the conjugate vaccine
to a level where the overall prevalence of pneumococcal
carriage has not been different in vaccinated and unvacci-
nated children [37]. Another study in South Africa also
found evidence of serotype replacement in a 9-valent vac-
cine trial among children where the prevalence of non-
vaccine serotypes increased from 21% in the controls to
39% in the vaccinated [43]. Nonetheless, it must be noted
that the prevalence of carriage changes much more grad-
ually than the incidence of invasive disease [44]. However,
serotype replacement is a crucial phenomenon in the use
of vaccination to prevent pneumococcal disease; its role,
dynamics and implications for the development and
widespread use of vaccines for the control of pneumococ-
cal disease requires further investigations. The rapid
turnover of serotypes in our study suggests that some
serotypes may be more rapid colonisers than others. Our
data provide some support for this notion: in Fig 2 we see
Figure 2 Seasonality of carriage among mothers and infants. Red 
= infant; green = mother. Thick = best fit; thin = 95% confidence limits.
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that the proportion of vaccine serotypes increases as the
infant ages. It is difficult to determine whether colony
half-life changes with infant's age because the length of
the interval between time points is strongly correlated
with age: the half-life/age interaction is heavily con-
founded with the possibility that the hazard of serotype
loss is not uniform with respect to the colony's age.
Although carriage is seasonal among both mothers and
infants, there is no evidence to suggest different seasonal-
ity of carriage between vaccine and non-vaccine sero-
Figure 3 (a) & (b) - Distribution of the observed and the expected number of serotypes each individual was found to be carrying at one or 
more time point. Red bar = expected. White bar = observed
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types. The higher carriage rates seen in the dry season
may explain the seasonality of invasive pneumococcal
disease among children in the Gambia [18]. However, it is
interesting to note that the two serotypes, 1 and 5 that
form over a third of serotypes causing invasive pneumo-
coccal disease in the Gambia are rarely carried [15,45].
We estimate that, while an infant is 9 times as likely to
carry a particular serotype if their mother does, the popu-
lation attributable fraction due to maternal carriage is less
than 10%, and this figure is probably inflated both by
infant-to-mother transmission (a mother's carriage on
average doubles in the first two months of her infant's
life) and simultaneous transmission to both from a third
party. We could not determine the extent of these
because of our study's key weakness was the infrequency
of swabbing and the extended time between swabs. We
have not extended our study to other members of the
family for example siblings and caregivers. These weak-
nesses were all as a result of the fact that the study was
not originally designed to describe the dynamics of car-
riage among this cohort.
Much of the analysis applied here relies on the assump-
tion that the pneumococcal serotypes are homogeneous.
While we appreciate that this will not always be true
(indeed, we demonstrate that vaccine and non-vaccine
serotypes do often differ) nevertheless we feel there is
value in estimating the average patterns and parameters
that this approach yields. The prevalence of most is too
low to make such estimates for individual serotypes. We
note, however, that if the lifespan of colonies were hetero-
geneous the marginal distribution of survival times would
no longer be exponential and estimates of half-life less
meaningful.
Conclusions
Nasopharyngeal pneumococcal carriage is highly preva-
lent among mother-infant pairs. Colonisation of the
nasopharyngeal tract in Gambian infants by S. pneumo-
niae is rapid and highly dynamic. Equilibrium between
acquisition and loss of colonies is reached by 2 m of age
and their half-life is only 1.9 m. The under-dispersed dis-
tribution of the number of serotypes carried by an infant
suggests that immunity or inter-serotype competition
may play a role in the dynamics. While there is a strong
association between maternal and infant serotype car-
riage, more than 90% of infant carriage is derived from
sources other than the mother. There is evidence that the
half-life of colonies, age-dependence of carriage and rela-
tive contribution of mother-infant transmission differ
markedly between the vaccine and non-vaccine sero-
types.
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